32.3 C
Vientiane
Friday, July 18, 2025
spot_img
Home Blog Page 131

Campaign360: A Resounding Success at Marina Bay Sands, Singapore

HONG KONG, June 3, 2025 /PRNewswire/ — Campaign Asia-Pacific, owned by Haymarket Media Limited, proudly concluded its flagship event, Campaign360, held on 27-28 May 2025 at the iconic Marina Bay Sands. The two-day conference brought together over 500 brand marketers from leading companies, including 3M, Adidas, Amazon, Chanel, Diageo, Fairprice, H&M, Johnson & Johnson, L’Oréal, Marriott, McDonald’s, Procter & Gamble, Shein, Singtel, The Coca-Cola Company, Trip.com, Unilever, and Volkswagen Group Singapore, to the Main Stage and Theatres.

Campaign360 2025
Campaign360 2025

The two-day conference showcased the latest innovations in marketing communications, supported by 52 industry partners and featuring 30 exhibition booths.

The event provided a platform for cutting-edge marcom technologies and solutions. Attendees enjoyed unlimited networking sessions, fostering collaboration and connection among industry leaders. Many reported forming valuable partnerships and exchanging innovative ideas that are set to shape the industry’s future.

One of the main highlights was the Focus Group sessions, which sparked great anticipation prior to the event. Participants selected from 20 engaging topics related to innovation & engagement, data & analytics, brand protection & reputation, market trends & collaboration, and talent & strategy. The two rounds of rotations allowed attendees to engage in one-on-one conversations, enhancing collaboration and idea exchange.

Over 100 top marketing speakers from around the globe graced the stage. Keynote speakers included Maren Costa, a Netflix star and climate advocate, who challenged attendees to rethink marketing amidst the climate crisis. She emphasised that brands often perpetuate overconsumption, urging the industry to focus on “leading better, not just selling more.”

Eric Sim, with 2.8 million followers on LinkedIn, shared insights on transcending industries and career stages, highlighting how a strong professional identity can unlock new opportunities.

Atifa Silk, Managing Director of Campaign Asia-Pacific, remarked, “Campaign360 has once again proven to be an invaluable platform for brand marketers. The overwhelming response and engagement reflect the industry’s commitment to innovation and collaboration. We extend our gratitude to our 52 partners for their support in making this event a success. We are excited to see how these discussions will shape the future of marketing.”

Campaign360 will return on 20-21May 2026, and our next Campaign Asia-Pacific event, Campaign Game Changers, will take place in October2025 in Singapore, covering the game-changing topics in the brand marketing industry. Stay tuned for more information! 

Thank you to PR Newswire for being the official media partner of Campaign360 in 2025.

For media inquiries, please contact: 
Danika Wong
danika.wong@haymarket.asia
Senior Marketing Manager 
Haymarket Media Limited 

About Campaign Asia-Pacific 
Campaign Asia-Pacific continues to provide unparalleled insights into the ideas, work, and personalities shaping the marketing-communications industry. By fostering open, honest dialogue and showcasing game-changing innovations, the platform remains an indispensable resource for marketing professionals across the globe. 
 
www.campaignasia.com

About Haymarket Media Limited
With over 70 market-leading brands and a presence in key markets such as the UK, US, Hong Kong, Singapore, and India, Haymarket Media Group, the parent company of Campaign Asia-Pacific, is dedicated to delivering specialist content and experiences that connect people and communities worldwide. Campaign360 2025 promises to be a milestone event, setting the stage for the future of marketing in Asia-Pacific and beyond.

www.haymarket.com 

The GBA Healthcare Group Partners with FWD Hong Kong to Offer Comprehensive Health Management Services from Prevention, Diagnosis and Treatment to Recovery

Providing FWD Hong Kong eligible customers with comprehensive services that integrate Chinese and Western medicine outpatient care, online consultations, laboratory tests and diagnostic imaging , dental care, colonoscopy screenings, and more.

HONG KONG, June 3, 2025 /PRNewswire/ — On April 22, 2025, Dr. Felix Lee and Dr. Kenny Kung, Co-CEOs of The GBA Healthcare Group(“GBAH”), joined the product launch event hosted by FWD Hong Kong to unveil the new Cross-Border Medical Vantage — GBAssure Outpatient Plan(”GBAssure ”). During the event, they highlighted the rising trend of Hong Kong residents seeking medical services in Mainland China and showcased how GBAH is helping meet this demand through its integrated, cross-border healthcare support system.

On April 14, 2025, FWD Hong Kong has officially launched the GBAssure Outpatient Plan. GBAssure utilizes GBAH’s extensive network of clinics and hospitals, offering clients a full range of healthcare services, from traditional Chinese medicine to Western medicine, and from general practice to specialty care#.

From Left to Right: Peter Lau, Chief Digital Officer and Head of Agency Development, FWD Hong Kong & Macau; Veronica Chong, Senior Regional Director, FWD Hong Kong; Dr. Kenny Kung, Co-Chief Executive Officer and Chief Medical Officer, The GBA Healthcare Group; Kelvin Yu, Chief Product Officer, FWD Hong Kong & Macau; Dr. Felix Lee, Co-Chief Executive Officer, The GBA Healthcare Group; Cally Wong, Assistant Vice President, Head of Health Management and Product Development, FWD Hong Kong.
From Left to Right: Peter Lau, Chief Digital Officer and Head of Agency Development, FWD Hong Kong & Macau; Veronica Chong, Senior Regional Director, FWD Hong Kong; Dr. Kenny Kung, Co-Chief Executive Officer and Chief Medical Officer, The GBA Healthcare Group; Kelvin Yu, Chief Product Officer, FWD Hong Kong & Macau; Dr. Felix Lee, Co-Chief Executive Officer, The GBA Healthcare Group; Cally Wong, Assistant Vice President, Head of Health Management and Product Development, FWD Hong Kong.

GBAssure spans Hong Kong, Macau, and six cities[1] in Mainland China within the Greater Bay Area (“GBA”). Within this network, clients and their designated family members[2] (with no limit on the number of individuals) will get access to family doctor services, available both in-person and via online consultation[3], that meet the same high-quality standards as those in Hong Kong. GBAssure also includes a range of additional services, including Traditional Chinese Medicine treatments[4], diagnostics imaging[4],[5], dental care[6], and colonoscopy screenings[7]. Additionally, clients will get convenient experiences such as Co-payment waiver  for non-prescription online consultations[8], electronic medical record sharing, and online direct payment.

This collaboration is the latest in a series of successful partnerships between GBAH and leading international insurers, such as AIA Hong Kong, Taiping Life Hong Kong, CTF Life, AXA Tianping Insurance, and Ping An Insurance Group. Leveraging its established medical network, GBAH is now expanding its services to FWD Hong Kong customers, providing a proactive, family-oriented approach to health management that covers everything from prevention, diagnosis and treatment to recovery.

As cross-border exchanges between Guangdong and Hong Kong continue to increase, Mainland China’s strong specialist capabilities, high medical efficiency, and cost-effective services have become increasingly recognized by Hong Kong and Macau residents. This has led to a surge in medical travel, with services such as Traditional Chinese Medicine, dental care, laboratory tests and diagnostic imaging, and specialist surgeries in high demand. However, challenges such as limited familiarity with Mainland medical institutions, lack of cross-border medical record sharing, and the inability to claim Hong Kong insurance for Mainland treatments remain.

GBAH has focused on developing the healthcare market in the GBA. Supported by regional governments, GBAH has formed public-private partnerships with Grade 3A/ Grade 3 hospitals and community health centers in the GBA to promote a Hong Kong-style family doctor model. This model integrates a Hong Kong-style, family doctor-centered approach to general practice and specialty collaboration and cross-border medical coordination, offering patients a seamless healthcare experience.

To date, GBAH has trained over 3,500 GOLDTM family doctors and nurses through its public-private collaborations. GBAH has also partnered with the 9 quality hospitals in Guangdong and Hong Kong, including CUHK Medical Centre, Gleneagles Hospital Hong Kong, Shenzhen Baoan People’s Hospital, and Guangzhou First People’s Hospital, and more. In addition, GBAH collaborates with more than 240 clinics across the GBA. Two partner hospitals have launched Hong Kong-Macau Drug and Medical Device Transit services. Meanwhile, GBAH has become one of the first enterprises authorized for cross-border personal information exchange within the GBA, offering a one-stop healthcare service system that includes general and specialist care, medicine, diagnostics testing and online direct payments.

In 2024, GBAH, in collaboration with seven Grade 3A hospitals/Grade 3 hospitals, introduced specialized services such as Hong Kong-style health checkups, cross-border imaging, and painless gastrointestinal endoscopy. Patients in need of medical care can visit the Hong Kong-Macau Residents Healthcare Services Centers located within these partner hospitals will benefit from the convenience of same-day appointments and diagnostic services using equipment that meets Hong Kong standards. To reduce duplicate testing, cross-border bilingual imaging services will include a secondary review by Hong Kong doctors, with bilingual Chinese-English reports, ensuring high-quality, cost-effective and cross-border diagnostic services.

Looking forward, GBAH plans to further expand its collaboration with insurance companies to launch a series of innovative health insurance products covering the GBA. GBAH aims to establish a cross-border healthcare network that connects community health centers, Grade 3A hospitals, and clinics across the region. In partnership with insurers, seeks to promote value-based health insurance solutions and implement a family doctor-centered, health-focused management model. This model will provide clients with comprehensive, full-cycle health management for their entire families, while also shifting insurance from a post-claim model to one that emphasizes proactive intervention. The goal is to reduce preventable health risks, improve overall public health, and create a more sustainable future for both the healthcare and insurance industries.

About FWD Hong Kong

FWD Hong Kong is part of the FWD Group, a pan-Asian life and health insurance business that serves approximately 30 million customers across 10 markets*. FWD Hong Kong is firmly positioned as a top five pan-Asian insurer by business scale in Hong Kong^. FWD Hong Kong has been assigned strong financial ratings by international agencies. It offers life and medical insurance, employee benefits, and financial planning. FWD’s customer-led and digitally enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance.

* Includes BRI Life in Indonesia

^According to Provisional Statistics on Hong Kong Long Term Insurance Business – January to September 2024, Insurance Authority of Hong Kong, as well as FWD’s own assessment based on market information, FWD ranks among the top five in both new business FYP ranking and new business case count. Calculated based on individual and group businesses. Pan-Asian insurers refer to multinational insurers currently having a well-established operation in the Asian market with multiple distribution channels.

 

About T he GBA Healthcare Group ( GBAH )

The GBA Healthcare Group (“GBAH”) was established in 2014, a mission driven healthcare company founded in Hong Kong that has been pioneering private public partnerships for healthcare services with various regional governments in the Greater Bay Area (GBA). GBAH is a strategic, controlling healthcare investment of Chow Tai Fook Enterprises Limited, the flagship private investment holding company of the Cheng Family in Hong Kong. Since its establishment, GBAH has delivered primary care training and accreditation to over 3,500 GOLDTM-certified family doctors and nurses in the GBA, jointly built over 240 GOLDTM private-public-partnership clinics in partnership with regional governments, and operated GOLDTM Hong Kong-Macau Residents Healthcare Services Centers within large-scale top-tier public hospitals, offering full-spectrum outpatient and inpatient care. Through such a vast service network, GBAH is creating innovative alternative payment models with health insurers, based on family medicine and preventive care practices, to implement value-based health insurance propositions. The goal of GBAH is to give everyone access to trusted and affordable healthcare, so that everyone can freely pursue their dreams without worrying about their health.

Learn More:
www.gbahealthcare.com.hk

# GBAssure only covers consultation with General Practitioner and Chinese Medicine Practitioner, please refer to product brochure and FWD Life Insurance Company (Bermuda) Limited (incorporated in Bermuda with limited liability) (“FWD Hong Kong”) website for details: www.fwd.com.hk. Customers have to bear all relevant cost incurred by receiving any specialist consultation.

[1] Designated Mainland GBA Cities currently include Guangzhou, Shenzhen, Zhuhai, Foshan, Dongguan and Zhongshan subject to FWD Hong Kong’s revision to the list of cities from time to time without prior notice.

[2] Designated family members include the Policy Owner’s parents, children, spouse, and the spouse’s parents.

[3] Online consultation is not applicable to an Insured / the User aged 5 years or below (actual age) on the date of the general practitioner online consultation. During the online consultation, the Insured / User must be physically present in the same District (i.e. Hong Kong or any one of the Designated Mainland GBA Cities, as the case may be) as the location of the clinic at which the Physician provides the online consultation.

[4] Referral from the Physician of GBAH’s is required for Chinese Medicine Practitioner Face-to-face Consultation and Laboratory Tests and Diagnostic Imaging.

[5] Prescribed list is applicable for Laboratory Tests and Diagnostic Imaging. FWD Hong Kong and GBAH reserve the right to amend the prescribed list from time to time without prior notice. No designated test from the customers is accepted.

[6] Dental Care is subject to prevailing terms and conditions as specified in the coupon.

[7] The colonoscopy coupon can be used by the Policy Owner or Insured/ User who is at 18 or above (actual age) at the time of receiving colonoscopy services and is subject to prevailing terms and conditions as specified in the coupon.

[8] The Co-payment waiver is applicable to benefit item 1(b) General Practitioner Online Consultation with Medicine Delivery (listed in the Benefit Schedule of product brochure of GBAssure) if no prescribed medication is provided after the online consultation.

The above product information does not contain full terms and conditions and is for reference only and is indicative of the key features of the product. For the geographical limitation of each benefit item available in the GBAssure Outpatient Plan, full and exact terms and conditions and the full list of exclusions of the product, please refer to its product brochure and FWD Hong Kong website at www.fwd.com.hk.

The above information about FWD Hong Kong and GBAssure Outpatient Plan are provided by FWD Life Insurance Company (Bermuda) Limited (incorporated in Bermuda with limited liability) (“FWD Hong Kong”) and for reference only and shall not be construed as the offer, sale or solicitation for the purchase of any insurance product outside Hong Kong. Different insurance products on the market have different coverage, terms and conditions, exclusions and product risks. In addition to understanding your own needs and affordability before purchasing insurance, you should also read the policy documents carefully to clearly understand the coverage and terms and choose a product that suits you. FWD Hong Kong does not make any express or implied explanations, representations or warranties regarding the accuracy, completeness or suitability of the information for any particular purpose. FWD Hong Kong is not responsible for any consequences arising from the use or reliance on this article and shall not bear any legal liability (including third party liability). Users should evaluate all the information contained in this article on their own or seek independent expert advice.

Connect to Care Global Launches to Drive Post-Aid Development Across Global South

Singapore-based consultancy offers political, digital, business-driven and South–South solutions to overcome reduction in Global North aid budgets.

SINGAPORE, June 3, 2025 /PRNewswire/ — Connect to Care Global (CTCG), a Singapore-based development organisation, officially launched today to help international agencies and regional partners across the Global South navigate a rapidly changing aid landscape. As the Global North reduces its traditional aid commitments, a post-aid world is emerging that demands smarter, faster, and more locally grounded solutions.

“It’s a critical time for all of us in the Global South as we grapple with a multitude of problems in the face of declining Global North aid budgets,” said Chandita Samaranayake, Founder and Director of CTCG. “Connect to Care Global is both a comprehensive response to this challenge and an opportunity to build a more resilient development sector across the Global South.”

Backed by a regional network of experienced consultants based across South and Southeast Asia, CTCG brings together deep local knowledge with cross-sector expertise in technology, strategic communications, and non-profit operations. The team includes former diplomats, advisors to governments, private sector and CSO leaders and has delivered projects in every part of Asia, offering a unique ability to bridge global strategic thinking with local execution.

While officially launching today, CTCG has been delivering for the past 12 months, including nutrition, water resource management and recycling projects in Sri Lanka, Indonesia and Rwanda. 

CTCG’s approach is built upon three core pillars:

  • Think and acting politically – by aligning with local power structures and governance dynamics
  • Adopting digital solutions – leveraging tech to scale impact across health, education, agriculture, governance, and finance
  • Building South–South cooperation – promoting peer learning, context-aware solutions, and regional capacity-building

The organisation’s fundamental approach relies on unlocking the power of local and regional talent. Designing projects that include local private sector stakeholders and align with government priorities while taking into account the priorities and needs of development sector partners.  

Now open for partnerships, Connect To Care Global invites development agencies, multilateral institutions, private sector organizations and foundations to collaborate on politically smart, digitally enabled, and regionally grounded programs.

For more information, please visit the CTCG website.

– END –

About CTCG

Connect to Care Global is a mission-driven consulting and implementation partner helping development actors accelerate sustainable impact across South and Southeast Asia. Headquartered in Singapore, CTCG combines regional expertise with global insights to support the next generation of development programs.

 

INCUBASE Studio Brings Unmissable Anime Experiences Across Asia: From Crayon Shinchan to Beloved BL Hits

HONG KONG, June 3, 2025 /PRNewswire/ — INCUBASE Studio is bringing anime to life across Asia with a wave of immersive experiences, including the newly launched “Crayon Shinchan: Space & Time Adventure Interactive Exhibition” and the popular “Delicious in Dungeon Exploration Exhibition” in Hong Kong. As a leading curator of anime exhibitions, the Studio continues to introduce beloved IPs to fans through dynamic storytelling and regional-first showcases.

INCUBASE Studio’s latest original curation “Crayon Shinchan: Space & Time Adventure Interactive Exhibition” debuted in Hong Kong and is open now until August 31.
INCUBASE Studio’s latest original curation “Crayon Shinchan: Space & Time Adventure Interactive Exhibition” debuted in Hong Kong and is open now until August 31.

New Shinchan Exhibition Opens in Hong Kong as Part of Asia Tour

The brand-new and highly anticipated “Crayon Shinchan: Space & Time Adventure Interactive Exhibition” is INCUBASE Studio‘s latest original curation, now officially open at Kai Tak Mall through August 31. Making its Hong Kong debut as part of an Asia tour, the exhibition is also the first interactive Crayon Shinchan showcase in the city and the first large-scale themed exhibition hosted at the prominent Kai Tak Mall. Drawing from the manga, anime and movies, the exhibition spans 5 themed zones and 9 exhibition areas filled with interactive games and mobile app integrations, offering a whimsical, time-traveling adventure for visitors of all ages.

INCUBASE Arena’s themed exhibits and pop-up stores

Meanwhile, the anime culture hub INCUBASE Arena brought the “Delicious in Dungeon Exploration Exhibition” to Hong Kong for the first time, featuring detailed recreations of iconic scenes, exclusive photo zones, and a special appearance by voice actor Asuna Tomari at the opening ceremony. The exhibition also includes a showcase of art replica by author Ryoko Kui, adding artistic depth to the experience. This marks the first project following INCUBASE Studio‘s strategic partnership with K11 Concepts Management, leveraging the K11 Experience ticketing platform to reach a broader audience.

Beyond large-scale exhibitions, INCUBASE Arena curates a wide range of pop-up stores and thematic events. Recent launches include the “Twittering Birds Never Fly” Pop-up Store, featuring art replicas, exclusive merchandise and photo spots from the globally loved BL manga, as well as “The Tower of God: The Workshop Battle” Pop-up Store bringing scene and costume displays and merchandise to fans. The “Sweetscape Art Exhibition” will take place during June 7 – 15, celebrating the creative work of 27 Hong Kong illustrators while supporting the local creative community.

INCUBASE Experiences beyond Hong Kong

INCUBASE Studio‘s footprint continues to grow across Asia. In Kuala Lumpur, the “Cardcaptor Sakura Exhibition: The Enchanted Museum” became the second major exhibit at INCUBASE Arena Malaysia, while the first-ever One Piece Asia Hunt has launched at SplashMania WaterPark, offering fans an immersive, real-world treasure hunt adventure.

Following successful runs in Hong Kong and Kuala Lumpur, the “Kamen Rider 50th Anniversary Exhibition” has now opened in Bangkok, alongside the massive “100% DORAEMON & FRIENDS Tour Thailand”, one of the largest Doraemon showcases in the world.

The acclaimed “One Piece: The Great Era of Piracy Asia Tour”, the first curation by INCUBASE Studio, has reached its 7th stop in Shanghai, Mainland China, and is set to continue to Pingtung in southern Taiwan from June 21.

“The Chainsaw Man Animation Exhibition” is currently on its Asia tour in Taipei following its debut in Hong Kong earlier this year. Its next stop is set for Seoul, South Korea this July, where it will be joined by the Tokyo Revengers and Oshi no Ko exhibitions, both concluding in June.

Promote anime culture through exhibition experiences

“As a curator, I believe that hosting diverse anime exhibitions not only celebrates the incredible works but also plays a vital role in promoting anime culture. We aim to connect with fans across Asia and beyond, creating immersive spaces where everyone can come together to share and celebrate their passion,” shared Sion Yip, Founder and CEO of INCUBASE Studio.

Through compelling curations and strategic collaborations, INCUBASE Studio is redefining anime experiences for fans worldwide, connecting generations through storytelling, design, and a shared love for anime culture.

About INCUBASE Studio

INCUBASE Studio curates diverse IP-themed exhibition experiences that celebrate and connect fandoms worldwide. The Studio brings stories to life by blending captivating content with engaging installations and interactive devices. Since its establishment in Hong Kong in 2021, INCUBASE Studio has been committed to realising and promoting Touring Experiences across Asia, pushing the boundaries of physical venues and experiences.

In 2024, INCUBASE Studio established INCUBASE Arena in Hong Kong and Malaysia as hubs for Japanese anime culture and entertainment experiences, continuously hosting a variety of popular anime IP exhibitions and related events to build a vibrant community for anime fans in both regions and the surrounding areas.

www.incubasestudio.com 

 

First Phosphate Closes Final Tranche of Oversubscribed Private Placement


Saguenay, Quebec – Newsfile Corp. – June 2, 2025 – First Phosphate Corp. (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce that it has closed the second and final tranche of its non-brokered private placement financing (the “Offering“), as further described in the Company’s news releases dated May 9, 2025 and May 28, 2025.

As part of both tranches of the Offering, the Company raised a total of $3,517,519 through the issuance of 7,275,309 Flow-Through Shares at a price of $0.35 for gross proceeds of $2,773,858, and 2,124,747 Hard Dollar Units at a price of $0.35, comprised of 2,124,747 Common Shares and 1,062,373 Warrants, for gross proceeds of $743,661.

Together with this Offering, the Company has raised to date a total of approximately $23.8 million in 7 management-led non-brokered private-placement financings since June 2022.

Under the final tranche of the Offering, the Company raised a total of $1,126,365 through the issuance of 2,883,429 Flow-Through Shares for gross proceeds of $1,009,200, and 334,757 Hard Dollar Units, comprised of 334,757 Common Shares and 167,378 Warrants, for gross proceeds of $117,165.

In total, in connection with the Offering, the Company paid $800 in cash finder’s fees, issued 471,152 Compensation Shares and advisory shares at a price of $0.35 per common share, and issued 444,867 Compensation Warrants, exercisable at a price of $0.50 per common share of the Company, until December 31, 2025, subject to an Accelerated Expiry Date. All securities issued under the Offering are subject to a four-month and one day statutory hold period in accordance with applicable securities laws. The Company intends to use the proceeds from the Offering as disclosed in the Company’s press release dated May 9, 2025. Capitalized terms used in this news release and not defined herein have the meanings given to them in the Company’s news release dated May 9, 2025.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Completion of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary approvals. There can be no assurance that any further securities will be sold under Offering.

About First Phosphate Corp.
First Phosphate (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) is a mineral development company dedicated to producing high-purity phosphate for the LFP battery industry. The Company is committed to sustainable extraction and purification with a low anticipated carbon footprint. Its vertically integrated model connects phosphate mining directly into the supply chains of North American battery producers. First Phosphate’s flagship project, the Bégin-Lamarche Property in Saguenay-Lac-Saint-Jean, Quebec, contains rare igneous anorthosite rock that yields high-purity phosphate with minimal impurities.

For additional information, please contact:
Bennett Kurtz
Chief Financial Officer
bennett@firstphosphate.com
Tel: +1 (416) 200-0657

Investor Relations: investor@firstphosphate.com
Media Relations: media@firstphosphate.com
Website: www.FirstPhosphate.com

Follow First Phosphate:
X : https://x.com/FirstPhosphate
LinkedIn: https://www.linkedin.com/company/first-phosphate

-30-

Forward-Looking Information and Cautionary Statements
This news release contains certain statements and information that may be considered “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements and forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved” and other similar expressions. In addition, statements in this news release that are not historical facts are forward-looking statements, including, among other things: the Company’s planned exploration and production activities; the properties and composition of any extracted phosphate; the Company’s plans for vertical integration into North American battery supply chains; and the receipt of all necessary approvals.

These statements and other forward-looking information are based on assumptions and estimates that the Company believes are appropriate and reasonable in the circumstances, which may prove to be incorrect, include, but are not limited to, the various assumptions set forth herein and in the Company’s public disclosure record including the short form base prospectus dated June 5, 2024, and the receipt of all necessary approvals.

There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. There can be no assurance that any opportunity will be successful, commercially viable, completed on time or on budget, or will generate any meaningful revenues, savings or earnings, as the case may be, for the Company. In addition, the Company will incur costs in pursuing any particular opportunity, which may be significant. These factors and assumptions are not intended to represent a complete list of the factors and assumptions that could affect the Company and, though they should be considered carefully, should be considered in conjunction with the risk factors described in the Company’s other documents filed with the Canadian and United States securities authorities, including without limitation the “Risk Factors” section of the Company’s Management Discussion and Analysis dated January 29, 2025 and Annual Report on 20-F dated July 8, 2024, which are available on SEDAR+ at www.sedarplus.ca. Although the Company has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in the forward-looking information or information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

The issuer is solely responsible for the content of this announcement.

Translators’ Voices: China shares technological achievements with the world for mutual benefit

BEIJING, June 3, 2025 /PRNewswire/ — May 30, 2025 marks the ninth National Science and Technology Workers Day. In the early morning of the previous day, Tianwen-2, the country’s first asteroid probe and sampling mission, soared into the sky, carrying with it humanity’s aspirations for the stars and the universe.

The nation will thrive when science and technology develops, and the country will be strong when science and technology becomes advanced. The book series of Xi Jinping: The Governance of China contains multiple important speeches on science and technology. In the article “Strive for Greater Strength and Self-Reliance in Science and Technology” included in the fourth volume of the book series, President Xi emphasized that science and technology respond to the call of the times and have a global impact; they belong to all of humanity. “We should participate to the full in global science and technology governance, contribute Chinese wisdom, and shape a philosophy of technology for good purposes, so that science and technology better serve human wellbeing, and enable China’s science and technology industry to contribute more to building a global community of shared future!”

In the fifth installment of the “Decoding the Book of Xi Jinping: The Governance of China” series, the Global Times focuses on the theme of “practicing the philosophy of technology for good purposes and polishing China’s new name card in scientific and technological innovation.” We continue to invite Chinese and international scholars, translators of the work, practitioners of its concepts, and overseas readers to share their insights, understandings and reflection on China’s philosophy of science and technology development and international cooperation.

In the fifth article of the “Translator’s Voices” column, Global Times (GT) reporter Ma Ruiqian talked to Tomokazu Ueno (Ueno), a Japanese expert at the Center for Asia-Pacific of China International Communications Group. Ueno was involved in the translation and editorial work for the Japanese editions of Xi Jinping: The Governance of China.

GT: China’s scientific and technological development over the past decades – especially in recent years – has drawn global attention. Some say that technological innovation has become a “new calling card” of China. Do you agree with this view? You’ve mentioned that the application of technology in everyday life has brought greater convenience to ordinary people. What experiences from your work and life in China have led you to feel this way?

Ueno: I fully agree with this view – technology has indeed become one of the symbols of China’s modernization. What impresses me most is how quickly technological applications are integrated into society and made practical. For example, when I first arrived in Beijing and rented an apartment through a real estate agency, I was amazed to find that the entire rental process could be completed through a smartphone app. At places like train stations and hospitals, online systems are also widely used, so there’s almost no need to wait in long lines like before.

What also shocked me was that not only young people, but even most elderly people can use smartphones proficiently. Nearly all purchases can be made via mobile payment, which brings great convenience to daily life. To be honest, after getting used to this lifestyle, every time I go back to Japan to visit family, I find it a bit troublesome to carry cash, a wallet, transportation cards and various point cards again.

GT: Yes, technological innovation not only facilitates the daily lives of ordinary people in China but also serves as a key driver for the high-quality development of related industries. In May, during an inspection tour in Central China’s Henan Province, President Xi, emphasized the importance of “technological empowerment” and “independent innovation.” You have witnessed firsthand how technology is empowering the logistics and agricultural sectors in Xinjiang. How do you view the significance of technological empowerment for the development of Chinese industries?

Ueno: When I was interviewing in the Xinjiang Uygur Autonomous Region, I was deeply impressed by the high level of mechanization in local agriculture. Not only are large tractors used during the harvest, but new agricultural technologies are also widely applied in planting methods, field management, product transportation, environmental protection and water conservation. Agricultural technology is widely applied across the board. I realized that in China, even agriculture – one of the most traditional industries – is actively embracing high-tech tools. This not only significantly increases farmers’ incomes but also strongly boosts local development.

This example shows that China clearly understands that in order to improve people’s livelihoods and help them lead better lives, it is essential to revitalize local industries and promote sustainable development in different regions. The key to achieving this is technological innovation. In China, progress in high technology is closely tied to improvements in living standards.

GT: The fourth volume of Xi Jinping: The Governance of China includes an article titled “Strive for Greater Strength and Self-Reliance in Science and Technology.” In the article, President Xi points out that “science and technology respond to the call of the times and have a global impact; they belong to all of humanity.” How do you understand the “global impact” of science and technology as mentioned by President Xi?

Ueno: The way I understand this is that science and technology know no borders – they can bring benefits to the entire world and help address global challenges. China has consistently emphasized contributing to the world through “Chinese wisdom” and “Chinese solutions,” and it has put this philosophy into practice. Chinese technologies and their applications have already played a role in many areas around the world – including environmental protection, poverty alleviation, industrial development and improvements in people’s livelihoods – achieving notable results.

There is no doubt that the path China is taking – one that respects the idea that science and technology respond to the call of the times and have a global impact – is the right path for today’s world.

GT: At the meeting with China’s sci-tech workers in 2024, President Xi said that Chinese modernization should be supported by sci-tech modernization. You will soon host the fifth season of Finding Answers in China, which also focuses on Chinese modernization. How do you understand the idea that science and technology “respond to the call of the times”? How do you think sci-tech modernization has contributed to the success of Chinese modernization?

Ueno: I believe that “responding to the call of the times” means that science and technology reflect the defining features of a given era and serve as a driving force that propels modern society forward.

One of my strongest impressions regarding this idea came during an interview I conducted for Finding Answers in China, when I spoke with a Japanese entrepreneur engaged in water treatment projects in China. He remarked that while some countries still only prioritize development at the expense of environmental protection – and some leaders even continue to question the reality of global warming – China, along with the global mainstream, has shifted toward emphasizing environmental.

Environmental protection technology is one of the most representative fields that respond to the call of the times, and I’ve personally witnessed how China has significantly increased its attention and investment in this area over the past decade. This perfectly embodies the principle of “green development” emphasized in Chinese modernization – using technology to resolve the tension between development and the environment, and striving for harmonious coexistence between humanity and nature.

GT: In his article “Strive for Greater Strength and Self-Reliance in Science and Technology,” President Xi stated, “We should participate to the full in global science and technology governance, contribute Chinese wisdom, and shape a philosophy of technology for good purposes.” In your view, what is the significance of China’s philosophy and practice of “technology for good purposes” for the international community, especially for the vast number of Global South countries?

Ueno: Science and technology have a dual nature – depending on how they are used, they can either advance human development or cause harm. The philosophy of “technology for good purposes” is essentially a profound proposition about how a country should make good use of its scientific and technological resources within the international community.

From a global perspective, developing countries with relatively weak scientific foundations have an even greater need for science and technology to achieve development. China not only makes active calls, but also takes concrete actions to share its technological achievements with these countries, aiming to bring benefits to all of humanity. This approach emphasizes not monopoly over technology and wealth, but sharing and mutual benefit. Such a philosophy helps narrow the development gap between nations and thereby promotes global stability and prosperity.

GT: What are your expectations for China’s further participation in global science and technology governance and its growing role in the future of technological development? In Japan, there are sometimes mixed views regarding China’s pursuit of self-reliance and its technological rise. What is your opinion on this? And what message would you like to share about bilateral cooperation in the field of science and technology?

Ueno: In interviews with Japanese companies operating in China, I’ve noticed that many of them are now not only setting up manufacturing bases in China but also relocating their research and development centers here. I believe there is already a solid foundation and a wealth of achievements in ChinaJapan cooperation in science and technology, with considerable potential for further growth. Looking ahead, I hope both sides can continue to expand collaboration based on their respective strengths.

However, especially since the beginning of this year, there seems to be a growing headwind against cooperation. Science, by its nature, is a pursuit of rationality. It is regrettable when irrational political interference obstructs scientific collaboration. China has not compromised under such pressure and continues to uphold the principle of win-win cooperation. I can sense that China is playing an increasingly important role in guiding the world toward the right path.

welzo Establishes New Subsidiary in Singapore to Accelerate Expansion into Southeast Asia

FUKUOKA, Japan, June 3, 2025 /PRNewswire/ — welzo Inc., an innovation-driven company in the agri-horticultural sector (Head Office: Hakata-ku, Fukuoka City, Fukuoka Prefecture; President and CEO: Yoshifumi Kanao), has established a wholly owned subsidiary, welzo Singapore PTE. LTD., in Singapore as of June 2, 2025. This move marks a significant step in accelerating its  expansion into the Southeast Asian market and strengthening its global business development.

Background and Purpose

welzo has been actively expanding its business both domestically and internationally. Considering the rapid growth and diverse opportunities in the Southeast Asian market, weve strategically chosen Singapore as its regional base. With its excellent business environment and international connectivity, Singapore serves as a key hub for accessing ASEAN countries.

Business Activities of the New Office

Its Singapore office will serve as a central hub for marketing and business development across Southeast Asia, focusing on the following key areas:

– Development and Execution of Marketing Strategies for Southeast Asia
  welzo will implement promotional initiatives tailored to the market characteristics and consumer trends of each country, aiming to enhance brand recognition and expand sales channels. The company will also actively participate in trade shows and collaborate with local partners on marketing efforts.

– Import and Export of Agricultural Products, Feed Ingredients, and Pet Supplies
  through partnerships with local agricultural and pet-related businesses, we will establish a responsive supply system.  The company will promote the export of high-quality, safe Japanese products and the import of raw materials that meet local needs.

– Building Local Partnerships and Optimizing the Supply Chain
  Its Singapore office will centrally manage logistics, customs, and quality control operations to establish a more efficient and flexible supply chain.

– Recruitment and Development of Local Talent
  we will actively recruit skilled local professionals to promote regionally rooted business operations.  The company aim to provide multilingual and culturally sensitive services.

This new office will serve as a core base for its Southeast Asian operations and is expected to play a pivotal role in future regional expansion and global business growth. By leveraging its  Singapore office, we will strengthen its  ability to deliver value tailored to local needs and foster co-creation with local communities.

The welzo Group remains committed to contributing to a sustainable global society by promoting environmentally and socially responsible business practices. Through collaboration and co-creation with diverse partners across regions and industries, we aim to deliver new value on a global scale.

Yoshifumi Kanao, President & CEO of welzo Inc.
Yoshifumi Kanao, President & CEO of welzo Inc.

Comment from Yoshifumi Kanao, President & CEO of welzo Inc.

“Singapore is not just a gateway to Southeast Asia—it’s a global hub where innovation and agriculture can converge. With this new subsidiary, we aim to deliver high-quality Japanese products to local markets while building sustainable partnerships rooted in mutual growth. This marks a crucial step in our journey toward global co-creation.”

Overview of the New Subsidiary

Company Name: welzo Singapore PTE. LTD.
Address: 80 Robinson Road #10-01A Singapore 068898
Date of Establishment: June 2, 2025
Main Business Activities: marketing in Southeast Asia; import/export of agricultural products, feed ingredients, and pet supplies

Company Overview: welzo Inc.

welzo Inc. is a specialized trading company that provides products and services to enrich lives and promote a sustainable society through food and agriculture. Formerly known as Nichiryu Nagase, the company celebrated its  101st anniversary in 2022 and changed the company name to welzo Inc. on January 1, 2023. With 24 offices across Japan, welzo primarily operates in the B2B sector, handling agricultural materials, home gardening supplies, and feed ingredients. The company actively collaborate with internal and external partners and leverages IT and AI technologies to address pressing societal challenges in Japan.

Head Office: 1-14-3 Hakata Ekihigashi, Hakata-ku, Fukuoka City, Fukuoka Prefecture
President and CEO: Yoshifumi Kanao
Established: August 1952 (Founded August 1921)
Capital: 470 million yen
Sales: 50.137 billion yen (FY ending December 2024)
Business: Specialized trading company handling agricultural materials, home gardening supplies, and feed ingredients

Jenscare released 30-day follow-up results of LuX-Valve Plus TRINITY study and 1-year follow-up results of JensClip TMVr at EuroPCR 2025

BEIJING, June 3, 2025 /PRNewswire/ — Jenscare Scientific Co., Ltd. (“Jenscare” or the “Company”) (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes of JensClip, a proprietary TMVr system, at EuroPCR 2025 in Paris, France.

30-Day Follow-up Results of LuX-Valve Plus TRINITY Study

TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation and high surgical risk. The study enrolled 161 patients from 20 centers around the world, among which, 18 centers were from France, Germany, Spain, Denmark, and the UK.

The average age of the patients is about 77 years old with an average STS score of 9.92% (14.45% of Roll-in group). For FAS group, 72.48% of the patients has atrial fibrillation, 32.20% has left heart surgery/intervention, 26.85% has pacemaker/ICD implanted. For Roll-in group, 91.76% of the patients has atrial fibrillation, 41.67% has left heart surgery/intervention, 25.00% has pacemaker/ICD implanted. Patients are combined with multi other comorbidities, which formed a poor baseline and increased the risks of surgical treatment or difficulties of other interventional therapies. Over 75% of enrollments utilized valve sizes between 55mm and 70mm. The results show that the device success rate is about 97%, and the average device operation time is around 41.60 minutes with the shortest time being 11 minutes.

The safety indicators show that the overall CEC-adjudicated composite events rate at 30-day is 14.8% of FAS group and 14.9% with Roll-in group included. For FAS group, cardiovascular mortality is 1.3%, the incidence of strokes and non-selective tricuspid/valve surgery/intervention post procedure are both 0.7%, major cardiac structural complications is 2.0%, severe bleeding (including fatal, life-threatening and extensive bleeding as defined by MVARC) is 4.0%, new pacemaker implantation due to AVB is only 8.7%. No events prevailed in myocardial infarction, new onset renal failure, major access site and vascular complications, and device-related pulmonary embolism. For Roll-in group, both non-selective tricuspid/valve surgery/intervention post procedure and new pacemaker implantation showed one event. And there are no events prevailed in cardiovascular mortality, myocardial infarction, strokes, new onset renal failure, severe bleeding, major cardiac structural complications, and device-related pulmonary embolism.

The efficacy indicators show that the tricuspid regurgitation (TR) grade, NYHA classification, and QoL improved significantly at 30 days. For FAS group, 95.7% of the patients show no above moderate TR. 84.1% of them show postoperative NYHA class I/II. KCCQ score increased by around 14 pts on average. For Roll-in group, 91.7% of the patients show no above moderate TR. 58.3% of them show postoperative NYHA class I/II. KCCQ score increased by around 18 pts on average.

Professor Thomas Modine concluded that LuX-Valve Plus TTVR system is an innovative device indicated for high-surgical risk patients with severe TR and demonstrates several advantages. First, it features radial-force independent anchoring mechanism, which is designed particularly for TV. Second, it indicates low demands on imaging quality, which is expected to significantly reduce device time. Third, it provides large size options, which enables wide applicability on large TV anatomies. The 30-day clinical outcomes of TRINITY trial demonstrate good safety and performances, with improvements in quality of life and low rate of composite adverse events. The wide application on large anatomy patients provides encouraging treatment options for severe TR patients, while current therapies are limited. Further follow-ups of TRINITY trial and the U.S. FDA clinical study on LuX-Valve Plus are underway.

One-Year Follow-Up Results of JensClip

The study of JensClip TMVr system is a prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of JensClip in application on patients with symptomatic degenerative mitral regurgitation (DMR) at high surgical risk. The study enrolled 114 patients from 18 centers in China with an average age of 71 years old.

The average age of the patients is about 71 years old with an average STS score of 7.65. 63.2% of the patients has hypertension history, 41.2% has coronary artery disease, 30.7% has atrial fibrillation, and 91.2% has pre-operative NYHA class III/IV. The results show that the device success rate at 30 days is about 97%, and the average device operation time is around 67.53 minutes.

The safety indicators show that all-cause mortality is 1.8%. The incidence of unplanned mitral valve intervention/surgery is 5.3%, and that of stroke is 1.8%. The incidence of renal failure, myocardium infarction, major bleeding, device releasing/locking failure, and clip related hemolysis are all 0.9%. No events prevailed in SLDA and device related air embolism.

The efficacy indicators show that the mitral regurgitation (MR) grade, NYHA classification, and QoL improved continuously at 1 year. 96.29% of the patients show no above moderate MR. 93.46% of them show postoperative NYHA class I/II. KCCQ score increased by around 20 pts on average. 6MWD increased by around 82m from the baseline.

Professor Xiangbin PAN concluded that JensClip is an innovative device intended for severe DMR, providing easy and reliable operation. The 1-year clinical outcomes demonstrated procedural safety and durable MR reduction.

About LuX-Valve Plus

LuX-Valve Plus, the proprietary TTVR system, is designed for patients with severe tricuspid TR and high surgical risk. LuX-Valve Plus breaks through multiple technical difficulties in tricuspid valve interventional therapy. With the design of innovative “interventricular septum anchoring” and “leakproof self-adaptive braided ring”, which enables non-radial anchoring of the valve implant and tend to effectively prevent AV Block. LuX-Valve series product is designated by the FDA as a breakthrough device, is enrolled in the Total Product Life Cycle Advisory Program (TAP) pilot of the FDA and is selected for the Expert Panel Scientific Advice Pilot by the EMA. As of the latest update, over 700 implantation cases have been completed worldwide with the LuX-Valve series products, and the longest follow-up record has been over 6 years.

About JensClip

JensClip, the proprietary TMVr system, features an innovative self-locking design, which is expected to effectively improve mitral regurgitation and reduce leaflet tension. The valve clip allows for flexible shape adjustments, which is expected to enhance procedural safety and improve intraoperative maneuverability. Furthermore, its one-piece release mechanism is designed to minimize potential mis-operation risks associated with staged detachment, effectively reducing device operation time.

About Jenscare

Jenscare is an innovative medical device company, established in 2011. The Company has achieved a complete product layout of interventional treatment solutions for different types of structural heart diseases, including tricuspid valve disease, mitral valve disease, aortic valve disease and so on. LuX-Valve series products, the core products, are innovative in the design concepts and treatment solutions for complex tricuspid anatomies. It is expected to become one of the first commercialized tricuspid valve replacement products in the world.